According to FutureWise analysis the market for refsum disease treatment in 2023 is US$ 1.48 billion, and is expected to reach US$ 2.33 billion by 2031 at a CAGR of 5.8%.
Refsum disease is an autosomal recessive genetic disorder. A major cause of refsum disease is the accumulation of fatty acids (phytanic acids) in the plasma and tissues. It is characterized by numbness or weakness in the feet and hands, as well as a lack of the peroxisomes enzyme, which breaks down phytanic acid. In this case, phytanic acid is not properly metabolized due to a malfunction of the enzyme-producing gene. A mutation in the PHYH gene causes the disorder. Aside from progressive vision loss (retinitis pigmentosa), peripheral neuropathy, muscle coordination failure (ataxia), and dry, rough, scaly skin (ichthyosis), refsum disease has several other symptoms. It is characterized by progressive loss of vision (retinitis pigmentosa), lack of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). Blood plasma and tissues accumulate fatty acids (phytanic acid) that cause refsum disease. A malfunction in the gene that produces the enzyme that metabolizes phytanic acid causes the disease. National Library of Medicine estimates that more cases of refsum disease are caused by mutations in the PHYH gene, while the remaining cases are caused by mutations in the PEX7 gene. Funding from the government and continuous improvement in reimbursement and regulatory policies contribute to the growth of the refsum disease market. Increasing awareness of rare and genetic disorders has also contributed to the refsum disease market's growth. The symptoms of refsum diseases, however, usually appear between the age of 10 and 20 years, such as night blindness, cerebellar ataxia, weakness in the legs and arms, anosmia, ichthyosis, and deafness. As a result, the appearance of late symptoms restrains the growth of the refsum disease market. The refsum disease market growth is hindered by complications related to the disease, such as cardiac abnormalities and cardiomyopathy.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Refsum Disease Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Refsum Disease Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.